Table 1.
Treatment | Mean Lifespan ± SD (Days) |
Maximum Lifespan (Days) | % Increase Lifespan |
Number of Worms |
p Value (Log-Rank Test) |
---|---|---|---|---|---|
N2 | 19.76 ± 0.51 | 33 | - | 143 | - |
N2 + 1% DMSO | 20.20 ± 0.49 | 29 | - | 108 | - |
N2 + 50 mM 6-OHDA | 13.61± 0.31 | 26 | −31.12 | 248 | ####, p < 0.0001 |
N2 + 50 mM 6-OHDA + 1%DMSO |
13.75 ± 0.35 | 27 | −30.41 | 224 | ####, p < 0.0001 |
N2 + 50 mM 6-OHDA + HLEA-P3 5 μg/mL |
16.36 ± 0.49 | 33 | 18.98 | 165 | ****, p < 0.0001 |
N2 + 50 mM 6-OHDA + HLEA-P3 25 μg/mL |
15.36 ± 0.43 | 29 | 11.71 | 142 | *, p = 0.0105 |
NL5901 | 16.28 ± 0.37 | 27 | −17.61 | 130 | ####, p < 0.0001 |
NL5901 + 1% DMSO | 15.02 ± 0.36 | 25 | −23.99 | 133 | ####, p < 0.0001 |
NL5901 + HLEA-P3 5 μg/mL | 18.92 ± 0.43 | 28 | 25.97 | 130 | ****, p < 0.0001 |
NL5901 + HLEA-P3 25 μg/mL | 18.71 ± 0.44 | 28 | 24.57 | 122 | ****, p < 0.0001 |
The hash (#) indicates a significant difference between normal N2 and PD models, #### p < 0.0001. The asterisk (*) indicates significant difference between the untreated group (DMSO) and HLEA-P3-treated groups, * p < 0.05, **** p < 0.0001.